Improvements in technology of the major imaging approaches have lead to advances in the clinic as well as in novel experimental approaches to investigate oncologic and normal biological processes at both the anatomical and molecular levels. In particular, the use of reporter genes in gene therapy vectors combined with imaging has allowed one to follow the progression of cancer in living animals without the need for surgical biopsy. One of the limitations in use of reporter genes is the inability to target the gene vector to the specific tumor directly within the host. The best vector would be one that can transduce tumor cells and maintain stable transduction and long-term expression. Ideally, this would be accomplished by direct injection into the bloodstream followed by homing of the vector to the tumor cells. Retroviral vectors and specifically lentiviral vectors are most suitable for this purpose since they will infect and stably integrate into host cell genome. Among retroviruses, lentiviruses are particularly useful since they can infect non or slowly dividing cells and therefore have been used for direct injection of tissues. There have been numerous previous attempts at modification of retroviral envelope for targeting purposes, but in general resulted in low viral titers and inconsistent specificity. For the first time we have successfully engineered a retroviral vector, both lentiviral and oncoretroviral, that can be utilized to retarget the specificity of the vectors to specific cell surface molecules. Of particular importance, these vectors have high specificity while maintaining high viral titers. In our recent published model system we demonstrated that intravenous injection of the vectors will lead to specific targeting of human P-glycoprotein expressed on the surface of metastatic melanoma in a mouse model. Together with this targeting vector, we believe that we can now take full advantage of the major advances in imaging technologies for cancer to develop novel approaches to address experimental questions in animals and in the future to improve diagnostic approaches in patients. The proposed studies address fundamental questions regarding the mode of action of the targeting vector and its utility for molecular imaging.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA120327-03
Application #
7558945
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Menkens, Anne E
Project Start
2007-04-01
Project End
2010-01-31
Budget Start
2009-02-01
Budget End
2010-01-31
Support Year
3
Fiscal Year
2009
Total Cost
$234,840
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Morizono, Kouki; Chen, Irvin S Y (2011) Receptors and tropisms of envelope viruses. Curr Opin Virol 1:13-8
Morizono, Kouki; Xie, Yiming; Olafsen, Tove et al. (2011) The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe 9:286-98
Morizono, Kouki; Ku, Amy; Xie, Yiming et al. (2010) Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins. J Virol 84:6923-34
Morizono, Kouki; Xie, Yiming; Helguera, Gustavo et al. (2009) A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. J Gene Med 11:655-63
Morizono, Kouki; Pariente, Nonia; Xie, Yiming et al. (2009) Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins. J Gene Med 11:549-58
Liang, Min; Pariente, Nonia; Morizono, Kouki et al. (2009) Targeted transduction of CD34+ hematopoietic progenitor cells in nonpurified human mobilized peripheral blood mononuclear cells. J Gene Med 11:185-96